These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29088328)

  • 21. [Antiplatelet drugs in prevention of complications of arteriosclerotic diseases: it is necessary to move beyond aspirin].
    Shalaev SV
    Kardiologiia; 2003; 43(6):84-7. PubMed ID: 13677328
    [No Abstract]   [Full Text] [Related]  

  • 22. Duration of Dual Antiplatelet Therapy in Coronary Artery Disease: a Review Article.
    Moseley AD; Collado FM; Volgman AS; Schaer GL; Snell RJ
    Curr Atheroscler Rep; 2016 Jul; 18(7):45. PubMed ID: 27260146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The art of delivering evidence-based dual antiplatelet therapy.
    Curry WJ; Chambers CE; Curry GW; Curry EW
    J Fam Pract; 2018 Dec; 67(12):758-766. PubMed ID: 30566110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of antiplatelet therapy across the spectrum of patients with coronary artery disease.
    Bhatt DL
    Am J Cardiol; 2009 Feb; 103(3 Suppl):11A-19A. PubMed ID: 19166708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are at least 12 months of dual antiplatelet therapy needed for all patients with drug-eluting stents? All patients with drug-eluting stents need at least 12 months of dual antiplatelet therapy.
    Brener SJ
    Circulation; 2015 Jun; 131(22):2001-9; discussion 2009. PubMed ID: 26034082
    [No Abstract]   [Full Text] [Related]  

  • 26. Are at least 12 months of dual antiplatelet therapy needed for all patients with drug-eluting stents? Not all patients with drug-eluting stents need at least 12 months of dual antiplatelet therapy.
    Becker RC; Helmy T
    Circulation; 2015 Jun; 131(22):2010-9; discussion 2019. PubMed ID: 26034083
    [No Abstract]   [Full Text] [Related]  

  • 27. Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients.
    Mackman N; Spronk HMH; Stouffer GA; Ten Cate H
    Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):726-732. PubMed ID: 29449336
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of novel antiplatelet agents in acute coronary syndromes.
    Luna M; Holper EM
    Curr Atheroscler Rep; 2015 Mar; 17(3):483. PubMed ID: 25663559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiplatelet for Coronary Artery Disease in Specific Condition "No Size Fits All".
    Setiadi BM; Hartono B; Prakoso AB; Lubis AC; Munandar RM; Munawar M
    Curr Pharm Des; 2018; 24(4):478-495. PubMed ID: 29424303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Personalized antiplatelet therapy for coronary artery disease patients: is this the future?
    Bonello L; Lemesle G; De Labriolle A; Barragan P; Camoin-Jau L; Paganelli F
    Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1525-32. PubMed ID: 19954314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coronary and peripheral artery atherosclerosis: what choice for antiplatelet therapy.
    Gresele P
    J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e72-e74. PubMed ID: 29538147
    [No Abstract]   [Full Text] [Related]  

  • 32. Optimal Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Majithia A; Bhatt DL
    Interv Cardiol Clin; 2017 Jan; 6(1):25-37. PubMed ID: 27886820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral antiplatelet therapy and percutaneous coronary intervention.
    Yan BP; Clark DJ; Ajani AE
    Expert Opin Pharmacother; 2005 Jan; 6(1):3-12. PubMed ID: 15709878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chinese expert consensus statement on dual antiplatelet therapy in patients with coronary artery disease.
    Han Y
    Eur Heart J; 2022 Mar; 43(13):1283-1285. PubMed ID: 34792118
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis.
    Panchal HB; Shah T; Patel P; Albalbissi K; Molnar J; Coffey B; Khosla S; Ramu V
    J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):533-43. PubMed ID: 23872509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Update ESC-Guideline 2017: Dual Antiplatelet Therapy].
    Massberg S; Polzin A
    Dtsch Med Wochenschr; 2018 Aug; 143(15):1090-1093. PubMed ID: 30060279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The treatment of clopidogrel resistance: triple antiplatelet therapy and future directions.
    Acikel S; Akdemir R; Cagirci G; Yesilay AB; Dogan M; Kilic H
    Int J Cardiol; 2010 Sep; 144(1):79-82. PubMed ID: 19131128
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
    Fujisue K; Sugiyama S; Ono T; Matsuzawa Y; Akiyama E; Sugamura K; Matsubara J; Kurokawa H; Kaikita K; Iwashita S; Sumida H; Hokimoto S; Oniki K; Nakagawa K; Matsui K; Ogawa H
    Circ Cardiovasc Interv; 2013 Aug; 6(4):452-9. PubMed ID: 23922147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease.
    Larsen SB; Grove EL; Neergaard-Petersen S; Würtz M; Hvas AM; Kristensen SD
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28780510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease.
    Geisler T; Kapp M; Göhring-Frischholz K; Daub K; Dösch C; Bigalke B; Langer H; Herdeg C; Gawaz M
    Heart; 2008 Jun; 94(6):743-7. PubMed ID: 17567647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.